Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Coral Calcium Claims Enforcement Action From FDA, FTC Urged By CRN

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

The Council for Responsible Nutrition advocates regulatory action against coral calcium marketers making "miracle cure" marketing claims in a May 15 letter to FDA and the Federal Trade Commission

You may also be interested in...



Coral Calcium Promoters Agree To Halt Disease Claims; FTC Lawsuit Pending

Dietary supplement promoter Robert Barefoot has entered into an agreement in principal with the Federal Trade Commission in which he will halt all claims about Coral Calcium Supreme's ability to treat cancer and other diseases while an FTC lawsuit is pending

Coral Calcium Promoters Agree To Halt Disease Claims; FTC Lawsuit Pending

Dietary supplement promoter Robert Barefoot has entered into an agreement in principal with the Federal Trade Commission in which he will halt all claims about Coral Calcium Supreme's ability to treat cancer and other diseases while an FTC lawsuit is pending

Coral Calcium Promoters Agree To Halt Disease Claims; FTC Lawsuit Pending

Dietary supplement promoter Robert Barefoot has entered into an agreement in principal with the Federal Trade Commission in which he will halt all claims about Coral Calcium Supreme's ability to treat cancer and other diseases while an FTC lawsuit is pending

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest News

Covis, CDER Lay Out Arguments Ahead Of Makena’s Accelerated Approval Withdrawal Hearing

FDA Vaccine Advisors Put Manufacturers On Notice: New Flu Vax Licensing Requirements May Be Coming

US FDA’s ODAC Pushes Back Against ‘Leading’ Questions

Medicaid Adoption Of Medicare CED Restrictions For Alzheimer’s Drugs Weighed By MACPAC

See All
UsernamePublicRestriction

Register

PS095475

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By